Date: 2013-10-31
Type of information: Commercialisation agreement
Compound: Oralair®
Company: Stallergenes (France) Greer Laboratories (USA)
Therapeutic area: Allergic diseases - Immunological diseases
Type agreement: commercialisation
Action mechanism: Oralair® is an allergen immunotherapy sublingual tablet consisting of five purified and calibrated pollen extracts: Perennial Ryegrass (Lolium perenne), Kentucky Bluegrass (Poa pratensis), Timothy Grass (Phleum pratense), Orchard Grass (Dactylis glomerata) and Sweet Vernal Grass (Anthoxanthum odoratum). To date, Oralair is available in 16 European countries and also continues to expand beyond Europe: following a positive start in Australia/New Zealand and Russia, the product was launched a few months ago in Canada, which makes it the first allergen immunotherapy tablet to be registered and marketed in North America.
Disease: grass allergy
Details:
Financial terms: Under the terms of the agreement, Greer will lead the sales and marketing efforts for Oralair® in the United States and Stallergenes will be responsible for tablet production and supply. Stallergenes will receive regulatory and commercial milestone payments totalling up to $120 million, plus royalties and a transfer price.
Latest news: